By the way, the snug cap is secured onto a patient’s head every time she undergoes chemotherapy.
This minimizes and in ’59 year old’ thought she had no choice to accept among the most dreaded sideeffects of chemotherapy, when Donna Tookes learned she had breast cancer last winter. Any time you look in the mirror, you remember you’re getting cancer treatment. Significant alopecia is problematic, said Klein. For women struggling through a difficult medical ordeal, the benefit is significant. Research published in 2008 in the journal ‘PsychoOncology’ looked at 38 existing studies on breast cancer treatment and quality of life problems, and found hair loss consistently ranked the most troubling consequences of treatment for women.
Plenty of breast cancer survivors report that even when their hair finally grows back after chemotherapy I know it’s often different in color or texture than the hair they had before, because of the timespan it requires the hair follicles to recover from the damage caused by the drugs.
The clinical trial is now in its final phase.
Actually the company behind the cap, Dignitana, should be submitting results to the Food and Drug Administration by the end of November, and hope to win FDA approval for the cap in 2015. Klein said overall, women who use the cap lose just 25 their hair percent.
Look, there’re whatsoever. Certainly, secretly, her husband began to conduct research.
He soon found out that Mount Sinai Beth Israel in New York was involved in a clinical trial on the device, known as the DigniCap System, that is worn by a patient during chemotherapy transfusions.
Okes had heard about some treatment in Europe that helps prevent chemorelated hair loss, though she didn’t know many details.
Her family could see that losing her hair will take a serious ll on her psyche. He wrote to friends in Sweden, who were able to obtain information about a brand new and innovative therapy called a scalp cooling cap. Now look. Tookes learned she had HER2 breast cancer, an especially aggressive form that can be difficult to treat, after a few subsequent tests.